Algeta opens Xofigo commercial manufacturing facility in Norway
The first alpha particle-emitting radioactive therapeutic agent, Xofigo has been approved by the US Food and Drug Administration (FDA) to treat castration-resistant prostate cancer (CRPC), symptomatic bone metastases